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Objective. The role of plasmacytoid dendritic cells (PDCs) and type I interferons (IFNs) in rheumatoid arthritis (RA) remains a subject of controversy. This study was undertaken to explore the contribution of PDCs and type I IFNs to RA pathogenesis using various animal models of PDC depletion and to monitor the effect of localized PDC recruitment and activation on joint inflammation and bone damage.
Methods. Mice with K/BxN serum-induced arthritis, collagen-induced arthritis, and human tumor necrosis factor transgene insertion were studied. Symptoms were evaluated by visual scoring, quantification of paw swelling, determination of cytokine levels by enzyme-linked immunosorbent assay, and histologic analysis. Imiquimod-dependent therapeutic effects were monitored by transcriptome analysis (using quantitative reverse transcriptase-polymerase chain reaction) and flow cytometric analysis of the periarticular tissue.
Results. PDC-deficient mice showed exacerbation of inflammatory and arthritis symptoms after arthritogenic serum transfer. In contrast, enhancing PDC recruitment and activation to arthritic joints by topical application of the Toll-like receptor 7 (TLR-7) agonist imiquimod significantly ameliorated arthritis in various mouse models. Imiquimod induced an IFN signature and led to reduced infiltration of inflammatory cells.
Conclusion. The therapeutic effects of imiquimod on joint inflammation and bone destruction are dependent on TLR-7 sensing by PDCs and type I IFN signaling. Our findings indicate that local recruitment and activation of PDCs represents an attractive therapeutic opportunity for RA patients.
Rheumatoid arthritis (RA) is a chronic multifactorial autoimmune disease (1) , and secondary autoinflammatory mechanisms are major contributors to its perpetuation (2) . The disease etiology involves different cell types, including innate and adaptive immune cells, which, along with resident synovial fibroblasts, interact to initiate and maintain an inflammatory milieu in the affected joint (3) . Our current understanding is that interaction between the genetic background and environmental factors triggers the disruption of tolerance to self antigens, which leads to activation of both B and T cells. This B and T cell activation in turn leads to a proinflammatory loop including cytokine production, aberrant adaptive response, neovascularization, and synoviocyte activation. To control or avoid this pathogenic interplay of cells in the synovium of RA patients, drugs that affect different cellular and/or molecular actors have been developed (4) , and major successes have been obtained in the past 15 years (5, 6) , especially with biologic agents that target various cytokines (7) . These treatments, however, have serious side effects in some cases (4) .
While currently available therapies aim to control the various actors in RA pathogenesis, dendritic cells (DCs), which are at the crossroads between innate and adaptive immune cells, have not received due attention as potential therapeutic targets. Of interest is a subpopulation of DCs, the plasmacytoid DCs (PDCs), which are defined by their capacity to secrete large amounts of type I interferons (IFNs). IFNs are inflammatory cytokines of paramount importance in the pathophysiology of many autoimmune or autoinflammatory diseases (8) . However, while the involvement of type I IFNs in RA pathogenesis is substantiated by several observations, such as an association with singlenucleotide polymorphisms in genes like IFN regulatory factor 5 (IRF-5) or IRF-8 (9) or the presence of the so-called "IFN signature" in the peripheral blood cells of RA patients (10, 11) , the precise effect of these cytokines remains a subject of controversy. This is particularly well evidenced by the dichotomy between the positive and promising action of type I IFNs administered intraarticularly in animal models (12) and the subsequent absence of biologic effects when these molecules were delivered in the context of unsuccessful clinical trials (13) . Hence, the precise role of type I IFNs, either beneficial or detrimental in RA pathogenesis, remains a subject of debate. Therefore, the potential to target these cytokines or the cells that produce them (PDCs) in order to expand the spectrum of molecules that may be prescribed to RA patients is still largely unexplored, despite obvious medical needs (among RA patients, 30-40% do not respond to biologic agents and complete remission is achieved in only 25-30% [4] ) and clear evidence demonstrating the presence of PDCs in the synovium of RA patients (14) .
The present study aimed to clarify this issue. In various mouse models of PDC depletion in which joint inflammation was triggered by arthritogenic K/BxN serum transfer, we observed worsened symptoms, suggesting that PDCs exert protective functions in RA. We next showed that mobilization and activation of PDCs upon topical application of the Toll-like receptor 7 (TLR-7) ligand imiquimod induces a notable reduction in the inflammation and bone erosion seen in 3 different mouse models of RA. This effect is accompanied by local recruitment of PDCs and reduced neutrophil infiltrates in the joint, as revealed by flow cytometry and transcriptome analysis. Importantly, the beneficial effects of imiquimod require type I IFN signaling. These observations highlight the potential efficacy of imiquimod, a molecule approved by the Food and Drug Administration, and its possible future use as the first topical treatment for RA.
MATERIALS AND METHODS
Mice. Ikaros-deficient mice (Ik L/L mice) have been described previously (15 The severity of joint inflammation was evaluated by measurement of paw thickness. Ik L/L mice exhibited a significant increase in joint swelling compared to controls from days 6 to 15 ( Figure 1A ). Visual scoring of the joints (considering redness and swelling) yielded similar results (Supplementary Figure 1D) . Figure 1H) . Taken together, these data indicate that the presence of PDCs is important to limit or resorb the joint inflammation triggered by serum transfer.
To further analyze the role of PDCs, we used 2 different ablation methods. First, mice were injected with 120G8 monoclonal antibody (mAb) (19) , which is specific for bone marrow stromal antigen 2 (tetherin/ CD317), predominantly expressed by mouse PDCs (20) , and then inflammatory arthritis was examined following K/BxN serum transfer. Paw swelling was significantly increased in mice receiving 4 injections of 120G8 mAb compared to those in which a control isotype antibody was injected ( Indeed, inflammation in the serum-transfer models of arthritis is particularly complement dependent (21) . To circumvent this, we induced PDC ablation in BDCA2-DTR-transgenic mice (22) . Using this approach, we first noticed that 5 successive injections of diphtheria toxin (on days 0, 2, 4, 6, and 8) partially phenocopied the Ik L/L mutation. Indeed, a significant increase in paw swelling (Supplementary Figure 3A) and systemic IL-6 secretion on day 5 ( Supplementary Figure 3B ) was observed in DTR-transgenic mice upon diphtheria toxin injection. However, qRT-PCR quantification of IL-6 and IL-1b transcripts on day 9 did not show any difference between control and BDCA2-DTR mice (Supplementary Figure 3C) . Accordingly, this protocol, although efficient, did not enable PDC depletion as extensive as that seen in in Ik L/L mice ( Supplementary  Figures 3D and E) . Therefore, consistent with our previous analysis of 120G8-depleted mice, BDCA2-DTRtransgenic animals did not exhibit enhanced arthritis characteristics upon histologic analysis ( Supplementary  Figures 3F-H) . Taken together, these data suggest a protective role of PDCs in inflammatory arthritis.
Dampened inflammation and reduced bone destruction upon PDC recruitment and activation in mouse models of RA. We next sought to recruit and activate PDCs with the aim of controlling experimental 2126 NEHMAR ET AL inflammatory arthritis. Imiquimod, a TLR-7 agonist, has been shown to induce psoriasis-like lesions upon topical application via the recruitment and activation of PDCs (23, 24) . We first tested the effect of a cream containing 5% imiquimod in the serum-transfer arthritis model (see Supplementary Video, available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40225/abstract). We observed that 2 topical applications of 0.75 lg of imiquimod on the inflamed joints on days 4 and 9 significantly reduced swelling (Figures 2A and B) . This was accompanied by a decrease in local IL-6 and IL-1b gene expression ( Figures 2C and D) and systemic IL-6 secretion (Figure 2E ). Of note, increased IFNb secretion was also observed after application of imiquimod on day 5 (Figure 2F ). This reduced inflammation enhanced bone quality, as seen by decreased erosion in the imiquimod-treated group compared to the vehicle-treated group (Figures 2G  and H) . Importantly, imiquimod application increased the population of periarticular PDCs in wild-type animals (compared to vehicle-treated mice, see Supplementary Figure 1F ), but not in Ik L/L mutant mice ( Figures 2I-K) , in which the treatment did not appear L/L mice (n = 4) by quantitative reverse transcriptase-polymerase chain reaction 9 days after serum-transfer arthritis induction. E and F, Quantification of serum IL-6 in wild-type mice (n = 6) and Ik L/L mice (n = 6) by enzyme-linked immunosorbent assay 5 days (E) and 9 days (F) after serum-transfer arthritis induction. G-I, Histomorphometric quantification of the area of inflammation (G), number of osteoclasts (H), and bone erosion area (I) in the hind paws of wild-type mice (n = 8) and Ik L/L mice (n = 6) 9 days after serum-transfer arthritis induction. J, Histomorphometric quantification of bone erosion in the hind paws of wild-type mice (n = 8) and Ik L/L mice (n = 6) 22 days after serum-transfer arthritis induction. In C-J, symbols represent individual mice; horizontal lines and error bars show the mean AE SEM. K and L, Representative images of tartrate-resistant acid phosphatase staining of the hind paws of wild-type mice (K) and Ik L/L mice (L) 9 days after serum-transfer arthritis induction. Original magnification 9 5. * = P < 0.05; ** = P < 0.01; *** = P < 0.001. Results are representative of at least 2 experiments.
to be effective either locally (as measured by paw swelling and visual score) or systemically (as measured by weight) (Figures 2L-N reflect the presence of a small proportion of PDCs, or alternatively, the response of imiquimod-responding cells, such as conventional DCs, expressing low levels of TLR-7.
Next, we induced joint inflammation using serum transfer and treated mice (on days 4 and 9) in the right hind paw only. Paw thickness and visual score did not differ significantly between the contralateral (untreated) To expand these observations to alternative models of RA (18), we also tested the effect of iterative imiquimod applications in DBA/1 mice with collageninduced arthritis (CIA). We initiated imiquimod applications on day 28, when the first signs of inflammation appeared, and then repeated the treatment 4 times (on days 31, 36, 41, and 46) . This led to a significant reduction in paw swelling compared to that in animals given the vehicle cream ( Figure 3A and Supplementary Figure 6 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40225/ abstract). This observation was corroborated by decreased IL-6 secretion in the imiquimod-treated group at the peak of symptoms (on day 50) (Figure 3B ). Histologic analysis of the paws revealed a marked reduction in the area of inflammation, the numbers of osteoclasts per hind paw, and, importantly, the bone erosion area (Figures 3E-G) . In addition, imiquimod application induced a significant decrease in the production of anti-type II collagen antibodies on day 50 (Supplementary Figure 7 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10. 1002/art.40225/abstract).
Finally, we administered serial imiquimod (or vehicle) applications to human TNF-transgenic mice, which are considered to be a relevant model of erosive arthritis (25) . Each mouse received treatments on 1 hind paw. As seen in Figure 4 , mice receiving imiquimod exhibited reduced arthritis symptoms, as monitored by histologic parameters.
Imiquimod-mediated therapeutic effects require type I IFN signaling. Having established the beneficial effect of topical imiquimod on joint inflammation, we aimed to describe its mechanism of action. First, we confirmed that topical application of imiquimod requires signaling through TLR-7 to induce its protective effects on joint inflammation. As shown in Supplementary Figure 8 (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.40225/abstract), application of imiquimod on days 4 and 9 had no beneficial effects on local arthritis symptoms (increased joint swelling and score) (Supplementary Figures 8A and B) or systemic arthritis symptoms (weight loss) (Supplementary Figure 8C) caused by K/BxN serum transfer in TLR-7 À/À animals. These observations correlate with the steady-state levels of circulating IL-6 seen on day 5 (Supplementary Figure 8D) and lack of PDC mobilization in the joints (Supplementary Figures 8E and F) .
We gathered additional details by first using flow cytometry to analyze the effects of imiquimod application on the innate immune cell populations present in the periarticular tissue (gating strategy is shown in Supplementary Figure 9 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40225/abstract). In addition, we performed a transcriptome analysis of this microenvironment. We noticed that application of imiquimod (but not the vehicle cream) to the joints of wild-type mice on days 4 and 9 following K/BxN serum transfer drastically reduced the CD45+ immune cell infiltrate (Figure 5A) . (See also Supplementary Figure 10 expression of markers of inflammation (IL-6 and IL-1) (Figures 2C-E) .
Furthermore, imiquimod induced the recruitment or the activation of PDCs, the proportion of which increased in the periarticular tissue of treated animals ( Figures 5B and F) , while absolute numbers remained steady (Supplementary Figure 10B) . These changes were accompanied by reduced numbers of neutrophils ( Figure 5D ) and conventional DCs (Figure 5E ). Consistent with these observations, we found that imiquimod induced changes in transcriptome profiling, such as decreased expression of the genes encoding the neutrophil chemoattractants CXCL1 and CXCL2 (26) , and increased expression of CCL2 and , and conventional DCs (CDCs) (E) in the periarticular tissue of vehicle-treated C57BL/6 mice (n = 4) or imiquimod-treated C57BL/6 mice (n = 6) 9 days after serum-transfer arthritis induction. In A-E, symbols represent individual mice; horizontal lines and error bars show the mean AE SEM. F, Proportions of conventional DCs, neutrophils, macrophages, and PDCs in CD45+ cells in the periarticular tissue of vehicle-treated C57BL/6 mice (n = 4) and imiquimod-treated C57BL/6 mice (n = 6) 9 days after serum-transfer arthritis induction. Bars show the mean AE SEM. G, Heatmap depicting transcriptional profiling in the paws of vehicle-treated C57BL/6 mice (n = 10) and imiquimod-treated C57BL/6 mice (n = 12) 9 days after serum-transfer arthritis induction. * = P < 0.05; ** = P < 0.01. CCL5, the products of which attract monocytes (27) and PDCs (28) (Figure 5G and Supplementary Figure 11 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.40225/abstract).
Importantly, the ratio of arginase 1 to inducible nitric oxide synthase indicated that infiltrating macrophages of imiquimod-treated mice are likely polarized toward alternative activation (M2) (29) , which is consistent with reduced IL-6, IL-1, and CD14 expression and reduced major histocompatibility complex class II staining in macrophages (Supplementary Figure 9D) . Of note, a clear IFN signature was evidenced by increased levels of IRF-7 and several IFN-stimulated genes (ISGs), such as Mx-1, IFN-induced protein with tetratricopeptide repeats 1, and CXCL10 transcription. The lack of changes in the expression of IFNb, IFNa4, and IFNa2 might reflect the fact that these genes are fast, non-lasting responders. Finally, the quantification of transcripts encoding matrix metalloproteinases (MMPs), which are important effectors participating in the bone damage following serum-transfer arthritis, confirms the protective effect of imiquimod. Indeed, expression of MMP-8 (whose knockout increases bone erosion, thereby classifying this MMP as "protective" [30] ) was augmented by imiquimod application, while Quantitative RT-PCR of a set of osteoclastrelated genes additionally showed reduced expression of the calcitonin receptor gene in the imiquimodtreated samples, consistent with the effects of the treatment on bone erosion, as seen on histologic examination. Transcripts encoding IL-10 remained below detection levels in this assay (results not shown). This analysis showed that topical application of imiquimod induced profound changes in the cellular cocktail that infiltrates the joint after serum-transfer arthritis induction. Most of these changes (such as M2 polarization of macrophages and the reduced proportion of neutrophils) likely account for the beneficial effects of imiquimod on joint inflammation and subsequent bone damage induced in mice with serum-transfer arthritis.
Finally, the transcriptomic "IFN signature" prompted us to evaluate the importance of type I IFN signaling in the antiinflammatory effects mediated by application of imiquimod. We examined the impact of imiquimod application in IFNAR À/À mice upon K/BxN serum transfer. The data demonstrated that absence of type I IFN signaling impairs imiquimod-dependent antiinflammatory effects, as determined by paw swelling, weight, IL-6 expression, and histologic features of the arthritic joints ( Figure 6 ). Taken together, our findings indicate a stepwise scenario whereby the sequence imiquimod/TLR-7/PDCs/type I IFN creates an appropriate environment for dampening joint inflammation and reducing subsequent bone damage.
DISCUSSION
The role of type I IFNs in the pathogenesis of RA remains a matter of controversy (10) . Several previous studies pointed to an association between increased type I IFN secretion and subsequent transcription of ISGs (the so-called "IFN signature" [33] ) in some RA patients (34) . This suggests that this cytokine family exerts proarthritogenic effects, which correlate with cases of disease induction in patients with hepatitis C virus treated with PEGylated IFN (35) . However, several mouse studies have challenged this concept. For instance, IRF-7-deficient mice are resistant to serumtransfer arthritis (36) , and several authors have reported beneficial effects of IFNb injections in mice (12) or rhesus monkeys (37) after arthritis induction. This led to a first clinical trial involving a small number of patients (n = 11) (38) whose promising results could not be reproduced when the number of subjects was scaled up (n = 209) (13) . Furthermore, a pathogenic role of type I IFNs is also difficult to reconcile with the correlation between a reduction in PDCs and the severity of arthritis shown in mice (39) and in humans (40) , since PDCs are the main source of type I IFNs. The most striking demonstration of the controversial role of type I IFNs in RA is perhaps illustrated by 2 publications from the same group reporting that IFNAR-knockout mice can either protect (41) or enhance (42) RA pathology, depending on the model.
In this study, using 3 models of PDC depletion, we provide substantial evidence for a protective role of PDCs in inflammatory arthritis (Figure 1 and Supplementary Figures 1-3) . We also managed to mobilize these cells at the inflamed site using topical application of imiquimod, a TLR-7 ligand. Imiquimod is the active component of a Food and Drug Administrationapproved topical treatment for superficial basal cell carcinoma and external genital warts, a process which is also PDC dependent (28) . This simple procedure exhibited remarkable efficacy for both resolution of inflammation and protection from bone damage. Importantly, we demonstrated that this protocol is efficient in 3 different models of arthritis characterized by different mechanisms of disease initiation and perpetuation (43) : the K/BxN serum-transfer model of arthritis, CIA, and human TNF-transgenic mice (Figures 2-4) . Finally, our flow cytometry and transcriptome analyses ( Figure 5 ) of periarticular tissues revealed that imiquimod application induces a TLR-7/PDC/type I IFN cascade that ultimately reduces the proportion of infiltrating neutrophils, the cytotoxic functions of which make them major contributors to RA pathology (44) . This is accompanied by an increased number of macrophages, whose polarization toward an alternatively activated phenotype likely contributes to the maintenance of an antiinflammatory milieu.
Consistent with a previous report describing CpGmediated inhibition of serum-transfer arthritis (45) , our data suggest that PDCs are majors players in the regulation of inflammatory reactions in the joint. While the precise mechanisms of the cellular cross-talk remain to be deciphered, both imiquimod-and CpG-mediated resolution of inflammatory arthritis appear to converge toward a reduction of the neutrophil infiltrate in the joint. A more thorough transcriptome analysis (using RNA sequencing) of the inflamed joint following imiquimod application is needed to identify signatures enabling the identification and activation status of the different innate immune cells present in this compartment (46) . However, our work extends these observations beyond the innate immunity-dependent models of arthritis in mice (namely, K/BxN serum transfer and human TNF-transgenic mice) to the CIA model in which T and B cell activation is required. Furthermore, the present work points to an essential role of type I (and possibly type III [47] ) IFN signaling in the protective effect of imiquimod following experimental arthritis. This is illustrated by the upregulation of the ISG CXCL10 which, through its antiangiogenic properties (48) , may also participate in this therapeutic process. In addition, our data are consistent with recent observations that enabled a re-evaluation of the role of IFNb and PDCs in the dampening of excessive inflammation occurring in various pathologic settings (49, 50) .
Up to now, manipulation of DCs for therapeutic purposes has been accomplished by means of adoptive transfer, for instance, of PDCs, which confer recovery from experimental autoimmune encephalomyelitis (49) , or of tolerogenic DCs in RA patients (51) . While infusion of autologous tolerogenic DCs appears feasible, and possibly beneficial (although not yet demonstrated) in large joints, this expensive procedure is unlikely to be applicable to the ever-growing number of patients in developed countries. Furthermore, it does not appear suitable for smaller joints in which injections remain a very painful procedure. We believe that mobilization of PDCs upon topical application of imiquimod, although not devoid of risks (52) , might represent an attractive, cost-effective, and efficient alternative for improving the management of RA. A future clinical trial should clarify this opportunity.
